<DOC>
	<DOCNO>NCT01280162</DOCNO>
	<brief_summary>An observational cohort malaria treatment study Cambodia .</brief_summary>
	<brief_title>Malaria Active Epidemiology Treatment Study</brief_title>
	<detailed_description>This active observational Cohort Study malaria epidemiology nest two arm , randomize , open label Treatment Study compare efficacy , safety , tolerability pharmacokinetics two versus three day course Dihydroartemisinin-Piperaquine ( DP ) develop uncomplicated malaria . At conclusion Cohort Study , subset volunteer document exposure Plasmodium vivax study treat primaquine presumptive anti-relapse therapy direct exoerythrocytic malaria stage P. vivax , follow passively additional 6 month .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>1 . Otherwise healthy volunteer , 1865 year age , eligible care RCAF facility , risk contract malaria 2 . Able provide inform consent 3 . Likely reside endemic area duration study 4 . Available followup anticipate study duration , agree participate duration study 5 . Authorized local commander participate study active duty 1 . History allergic reaction contraindication DHA piperaquine 2 . Significant acute comorbidity require urgent medical intervention 3 . Pregnant lactate female , female childbearing age agree use highly effective method birth control study 4 . Clinically significant abnormal EKG , include QTc interval &gt; 500 ms. 5 . Judged investigator otherwise unsuitable study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Plasmodium falciparum , Plasmodium vivax</keyword>
</DOC>